Lean mass on a GLP-1: what the trials that measured it found
The most-quoted number in this argument comes from 160 people. In the body-composition substudy of SURMOUNT-1, tirzepatide patients lost 21.3% of their weight, 33.9% of their fat mass and 10.9% of their lean mass — and roughly 75% of what came off was fat and 25% was lean, in the drug arm and the placebo arm alike. That last clause is the part that keeps getting dropped.
What this comes down to
- The SURMOUNT-1 substudy scanned 160 of the trial's 2,539 participants at baseline and week 72. About 75% of weight lost was fat and 25% lean, in both arms.
- In a separate 24-week randomized trial in 101 adults with chronic kidney disease, semaglutide changed lean body mass by -2.5 kg against placebo, with a confidence interval crossing zero.
- Only six randomized trials in humans name lean mass or fat-free mass alongside semaglutide or tirzepatide. The same filter returns 413 randomized trials of those drugs.
- Drugs aimed specifically at preserving lean mass during tirzepatide weight loss are now in randomized phase 2 testing, which is the clearest signal that the field treats this as unsettled.
The substudy everybody is quoting
SURMOUNT-1 randomized 2,539 adults to tirzepatide or placebo for 72 weeks[2]. A subset of 160 of them — 124 on pooled tirzepatide doses, 36 on placebo — had dual-energy X-ray absorptiometry scans at baseline and at week 72. Change from baseline in that subset was -21.3% for body weight, -33.9% for fat mass and -10.9% for lean mass on tirzepatide, against -5.3%, -8.2% and -2.6% on placebo, all with p below 0.001[1].
The authors then state the proportion, which is the sentence that travels: of the body weight lost, approximately 75% was fat mass and 25% was lean mass, for tirzepatide and for placebo alike, and that split stayed consistent across most subgroups they looked at by sex, by age and by how much weight came off.
A scan's lean compartment is everything that is neither fat nor bone mineral: skeletal muscle, yes, but also organ tissue, connective tissue and a great deal of water. Losing weight reduces the fluid and the tissue that supported the mass. That's why the placebo arm lost the same proportion, and why the interesting question isn't whether lean mass falls but whether strength and function fall with it — which a body-composition scan doesn't measure.
What the semaglutide side has
Less, and in a narrower population. The clearest randomized measurement comes from a prespecified analysis of a 24-week trial in 101 adults with chronic kidney disease and overweight or obesity, without type 2 diabetes, using bioimpedance spectroscopy rather than a scan. Against placebo, semaglutide 2.4 mg changed total body weight by -9.1 kg, lean body mass by -2.5 kg and fat mass by -3.9 kg[3]. Only the weight change had a confidence interval clear of zero; the lean mass interval ran from -6.6 to 1.6.
That is a small trial in people with kidney disease, measured with a different instrument, and it shouldn't be read as the semaglutide answer to the tirzepatide substudy. It's what exists.
PubMed, via the E-utilities API
(semaglutide[tiab] OR tirzepatide[tiab]) AND ("lean mass"[tiab] OR "fat-free mass"[tiab] OR "lean body mass"[tiab]) AND "randomized controlled trial"[pt] AND "humans"[mh]Returned 6. Positive control — semaglutide or tirzepatide, identical filter with no body-composition term — returned 413 through the identical filter in the same session.
Six against 413 is the finding. The six, read by title, are the SURMOUNT-1 substudy, the kidney-disease analysis, a phase 2 trial of a lean-mass-preserving drug, a pharmacometric modeling paper on tirzepatide body composition, a 2020 substudy comparing semaglutide with canagliflozin in type 2 diabetes, and a 2017 study of appetite and energy intake. The question the whole internet is arguing about has been measured in a handful of substudies of trials designed to measure something else.
The field's own answer: build a drug for it
If the question were settled, nobody would be running trials on it. A randomized, double-blind, placebo-controlled phase 2 trial of apitegromab for lean mass preservation during tirzepatide-induced weight loss was published in July 2026[4]. We cite that for its design and its existence: the PubMed record carries no abstract, and nothing on this page is drawn from one.
A lower dose produces less weight loss, and if the 75-25 split holds, less of both compartments. It doesn't follow that a lower dose protects lean mass — no trial has tested a microdose schedule against a label one for body composition. What microdosing is, and what it has and has not been shown to do, is its own article.
The other thing worth holding beside the substudy is what happens on the way back down. When the drug stops and the weight returns, the composition of the regained weight isn't guaranteed to match the composition of what was lost — and the withdrawal trials measured the weight without settling that. The frequency tables for everything else these drugs do are in the side-effect article.
Questions people actually ask
How much muscle do you lose on a GLP-1?
Nobody has measured muscle directly in a large trial. The best randomized figure is from a scan substudy of 160 SURMOUNT-1 participants, where lean mass fell 10.9% on tirzepatide over 72 weeks while body weight fell 21.3% — approximately 75% fat and 25% lean of the weight lost. The placebo arm lost the same proportions, and a scan's lean compartment includes water and organ tissue as well as muscle.
Is the 25% lean mass figure unusual?
It is close to what the same substudy's placebo arm produced, which is the most useful comparison available. The substudy reported roughly the same fat-to-lean split for placebo participants who lost weight, and that consistency held across subgroups by sex, age and the amount of weight lost.
Does resistance training change this?
Not something these trials tested. None of the six randomized trials naming lean mass alongside semaglutide or tirzepatide was designed to compare an exercise program against none in people taking the drug. Anything stated more confidently than that is being extrapolated from weight-loss research that did not involve these drugs.
Are there drugs that preserve lean mass on a GLP-1?
There are candidates in randomized testing. A placebo-controlled phase 2 trial of apitegromab for lean mass preservation during tirzepatide-induced weight loss was published in Nature Medicine in July 2026. A phase 2 trial isn't an approval and isn't evidence that anything works; it is evidence that the field regards the question as open.
Sources
Every source here was fetched and read for this article, with the identifier taken off the record that came back and the claim it supports written down beside it. All of it was read in September 2026, the same session the rest of this page draws on.
- 1.Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes, Obesity and Metabolism, 2025. PMID 39996356 · doi:10.1111/dom.16275The substudy of 160 of 2,539 SURMOUNT-1 participants scanned by DXA at baseline and week 72; changes of -21.3% body weight, -33.9% fat mass and -10.9% lean mass on pooled tirzepatide doses against -5.3%, -8.2% and -2.6% on placebo, all p below 0.001; and approximately 75% of weight lost as fat and 25% as lean mass for both tirzepatide and placebo, consistent across most subgroups.
- 2.Tirzepatide Once Weekly for the Treatment of Obesity. The New England Journal of Medicine, 2022. PMID 35658024 · doi:10.1056/NEJMoa2206038The parent trial the substudy sits inside: 2,539 adults randomized 1:1:1:1 to tirzepatide 5, 10 or 15 mg or placebo for 72 weeks, with mean weight change of -15.0%, -19.5% and -20.9% against -3.1% on placebo.
- 3.Effects of Semaglutide on Body Composition and GFR: A Prespecified Analysis of the SMART Trial. Clinical Journal of the American Society of Nephrology, 2026. PMID 42308057 · doi:10.2215/CJN.0000001051A prespecified analysis of a randomized placebo-controlled double-blind trial in 101 adults with chronic kidney disease and overweight or obesity without type 2 diabetes, in which 24 weeks of semaglutide 2.4 mg weekly changed total body weight by -9.1 kg (95% CI -11.0 to -7.2), lean body mass by -2.5 kg (95% CI -6.6 to 1.6) and fat mass by -3.9 kg (95% CI -7.8 to 0.0) against placebo, measured by bioimpedance spectroscopy.
- 4.Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial. Nature Medicine, 2026. PMID 42260100 · doi:10.1038/s41591-026-04440-4The existence and design of a randomized, double-blind, placebo-controlled phase 2 trial of a lean-mass-preserving agent given during tirzepatide weight loss, published July 2026. Cited for design and existence only: the PubMed record carries no abstract and no result is claimed here.
Key figures